Kygent Therapeutics

Kygnet Therapeutics is a biopharmaceutical R&D company. The company has developed a new product, KY-001, which is a direct inhibitor of TEAD-YAP protein-protein interaction for the treatment of advanced solid tumors with abnormal Hippo signaling pathways. In rapidly growing tumors, the Hippo signaling pathway also plays an important role. YAP and TEAD are two key transcription factors in the Hippo signaling pathway, and their interaction is a crucial regulatory step within this pathway.